Small Molecules

all catalysts(0)

nothing on the calendar yet

News(10)

• STAT+: One of the most consequential years for cancer treatment, ever
  Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.
  stat · 20h ago
• Kolon TissueGene cuts 37 US staffers after Phase 3 fail
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
  BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.
  fiercebiotech · 2d ago
• Capricor soars on potential FDA review extension, filing amendments
  Capricor Therapeutics’ CEO Linda Marbán believes the FDA is willing to work with the biotech as the Aug. 22 deadline approaches for its Duchenne muscular dystrophy cell therapy deramiocel, with the…
  biospace · 6d ago
• ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
  BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.
  fiercebiotech · 6d ago
• Chutes & Ladders—Former Legend CEO lands at K2
  Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…
  fiercebiotech · 7d ago
• Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
  Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
  fiercebiotech · 8d ago
• With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
  AI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.
  biospace · 9d ago
• Building Resilience for the Future of Biopharma Innovation
  How can industry build resilience as science advances? WuXi AppTec Co-CEO Dr. Steve Yang shares his perspective on the future of biopharma innovation.
  fiercebiotech · 9d ago
• BMS picks Texas for new $2.3B manufacturing campus
  Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
  biospace · 10d ago